Baar-Zug, 27 November 2012
Partners Group, the global private markets investment manager, acts as one of the Mandated Lead Arrangers and Underwriters, on behalf of its clients, for the mezzanine debt financing of UK headquartered specialty pharmaceuticals companies, Mercury Pharma and Amdipharm, which have been acquired by Cinven.
Mercury Pharma and Amdipharm are each specialty healthcare firms involved in the marketing and sales of niche prescription off-patent drugs. The two companies will be merged and, together, the companies offer a broad and well diversified portfolio of mature pharmaceutical products. The credit quality is reinforced by its leading position in its core niche markets, its geographical diversification as well as strong cash flow generation.
René Biner, Partner and Head Private Finance at Partners Group, comments: "The merger of Mercury Pharma and Amdipharm makes strong commercial sense and we are excited to have the opportunity to facilitate the combination and support the further growth of these two leading specialty pharmaceuticals companies. With this financing, Partners Group will have deployed mezzanine capital in eleven deals globally this year in high quality companies such as BSN Medical, CPA Global, Wood Mackenzie and Aenova for example. We are delighted to be able to add such a strong company to our portfolio."
The mezzanine financing is subject to market standard conditions including senior lender consent and is expected to close in the coming weeks.